ReviewOncology letters2018
Clinical significance of blood-based miRNAs as biomarkers of non-small cell lung cancer.
Review in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- The importance microRNAs as a biomarker in lung cancer.Acta bio-medica : Atenei Parmensis · 2023Pooled it
- Circulating miR-107, miR-199, and miR-485 Have High Diagnostic Potential in Non-small Cell Lung Cancer: An Exploratory Study.Clinical Medicine Insights. Oncology · 2026Article
- TGF-β1/miR-30d-5p axis regulating the expression of EMT key factors to induce apoptosis of lung cancer cells.Heliyon · 2024Article
- [Screening of immune related gene and survival prediction of lung adenocarcinoma patients based on LightGBM model].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2024Article
- Recent advances in the roles of exosomal microRNAs (exomiRs) in hematologic neoplasms: pathogenesis, diagnosis, and treatment.Cell communication and signaling : CCS · 2023Review
- FURIN correlated with immune infiltration serves as a potential biomarker in SARS-CoV-2 infection-related lung adenocarcinoma.Clinical and experimental medicine · 2022Article
- Article
- A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer.Journal of clinical laboratory analysis · 2022Article
- Review
- miR-421 promotes the viability of A549 lung cancer cells by targeting forkhead box O1.Oncology letters · 2020Article
- A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.Journal of translational medicine · 2020Article
- Prognostic role of macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the lung.Thoracic cancer · 2019Article
- MiR-1246 Promotes Metastasis and Invasion of A549 cells by Targeting GSK-3β‒Mediated Wnt/β-Catenin Pathway.Cancer research and treatment · 2019Article
- Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors.BMC cancer · 2019Article
- Emerging Function and Clinical Values of Exosomal MicroRNAs in Cancer.Molecular therapy. Nucleic acids · 2019Review
- Prognostic role of Rab27A and Rab27B expression in patients with non-small cell lung carcinoma.Thoracic cancer · 2019Article
- Comprehensive clinical implications of homeobox A10 in 3,199 cases of non-small cell lung cancer tissue samples combining qRT-PCR, RNA sequencing and microarray data.American journal of translational research · 2019Article
- Quantitative Detection of miRNA-21 Expression in Tumor Cells and Tissues Based on Molecular Beacon.International journal of analytical chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer. However, the predicted 5-year survival rate of patients with NSCLC is only 15.9%. microRNAs (miRNAs) are single-stranded, noncoding RNA molecules that are easily detectable in blood in a non-invasive manner, with features of stability, reproducibility and consistency in blood. Therefore, miRNAs derived from blood are able to have a significant impact on NSCLC diagnosis, metastasis and targeted therapies. Compared with the clinical protein markers carcinoembryonic antigen, cytokeratin fragment 21-1 and cancer antigen-125, blood-based miRNAs also display a higher diagnostic efficacy in NSCLC. Exosomal miRNAs are identified to be easily measured and have the potential to be used as diagnostic biomarkers in NSCLC, therefore providing an alternative method of biopsy profiling. The miRNA profile in exosomes is similar to the profile in primary tumor, meaning that this feature may be a powerful tool for NSCLC clinical diagnosis and targeted therapies. The focus of the present review was the clinical significance of blood-based exosomal miRNAs in diagnosis, prognosis, metastasis and targeted therapies of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.